secwatch.observer — SEC 8-K summary
======================================

Issuer:     Summit Therapeutics Inc. (SMMT)
CIK:        0001599298
Form:       8-K
Filed at:   2026-08-05T11:32:20+00:00
Accession:  0001599298-26-000071
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Summit expands ivonescimab into bladder cancer with Phase II/III HARMONi-GU1 trial
--------------------------------------------------------------------------------

- Ivonescimab plus enfortumab vedotin (EV) vs pembrolizumab plus EV as 1L therapy for locally advanced/metastatic urothelial carcinoma.
- Phase II/III trial aims to enroll ~800 patients; Phase III endpoints are PFS and OS.
- Global site activations planned to begin by Q4 2026.
- Ivonescimab now in 16 Phase III trials across multiple tumor types including lung, colorectal, and bladder.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000071/0001599298-26-000071-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1599298/000159929826000071/smmt-20260805.htm
  HTML page:      https://secwatch.observer/filing/0001599298-26-000071

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer